Cambridge Investment Research Advisors, Inc. Precision Biosciences Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.97 - $45.0 $970 - $45,000	-1,000 Reduced 6.16%	15,230 $18,000
Q3 2022 Oct 17, 2022	BUY	$1.22 - $40.8 $1,220 - $40,800	1,000 Added 6.57%	16,230 $0
Q2 2022 Jul 13, 2022	SELL	$1.15 - $3.34 $358 - $1,042	-312 Reduced 2.01%	15,230 $24,000
Q1 2022 May 12, 2022	BUY	$2.96 - $7.76 $46,004 - $120,605	15,542 New	15,542 $47,000
Q4 2021 Feb 03, 2022	SELL	$7.4 - $11.66 $90,553 - $142,683	-12,237 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$9.18 - $14.15 $17,625 - $27,168	-1,920 Reduced 13.56%	12,237 $141,000
Q2 2021 Aug 10, 2021	BUY	$8.07 - $12.52 $32,280 - $50,080	4,000 Added 39.38%	14,157 $177,000
Q1 2021 May 07, 2021	SELL	$8.57 - $15.79 $21,750 - $40,075	-2,538 Reduced 19.99%	10,157 $105,000
Q4 2020 Feb 04, 2021	BUY	$5.98 - $12.47 $75,916 - $158,306	12,695 New	12,695 $105,000

Others Institutions Holding DTIL

# of Institutions

Shares Held

2.56M

Call Options Held

Put Options Held

View Full List

About PRECISION BIOSCIENCES INC

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

More about DTIL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account